Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicadrostat plus empagliflozin vs placebo plus empagliflozin in type 2 diabetes, hypertension and established CVD
NCT07064473Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 51
01
Overview
A Phase 3 trial of vicadrostat in heart failure (HF), cardiovascular disease (CVD), sponsored by Boehringer Ingelheim. Started Jul 2025; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
heart failure (HF)cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT07064473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064473.